3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Hematologic Neoplasms
4
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Leukemia
1
Glioma
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
ponatinib
4
fludarabine
4
Cyclophosphamide
3
fludarabine phosphate
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Imatinib Mesylate
2
Busulfan
2
Bone Marrow Transplantation
2
trametinib
1
tetulomab tetraxetan lu-177
1
ruxolitinib
1
pertuzumab
1
nirogacestat
1
nilotinib
1
gilteritinib
1
emvododstat
1
dabrafenib
1
bosutinib
1
blinatumomab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
Trastuzumab
×
Other hematologic neoplasm
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled